Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Study Validates High Tolerability of ResistAid - Nutraceuticals World
Research

Study Validates High Tolerability of ResistAid

A new study shows that ResistAid, a proprietary immune ingredient from Lonza, Basel Switzerland, has very good tolerability. The double-blind, randomized, placebo-controlled clinical trial was published in the November issue of the Food and Nutrition Sciences (Vol. 3, No. 11, p. 1533-1538), and was conducted by analyze & realize AG. The study interviewed a total of 199 healthy participants, who received either 4.5g ResistAid or placebo for a 12-week period. To examine tolerability based on safety parameters, the research recorded the number of adverse events and changes in various clinical and laboratory parameters, as well as the global evaluation of tolerability by investigators and subjects, as compared to placebo.
“The tolerability was rated as “very good” or “good” by the investigators for 99% of the subjects, and by 98 % of subjects in self-assessment with no statistical differences to placebo,” says Barbara Grube, M.D., coordinating investigator and lead author of the study. “There were no differences concerning the incidence of adverse events between the two groups. Therefore, the intake of ResistAid over a period of 12 weeks can be considered as safe as placebo.” For further information: http://www.scirp.org/journal/PaperInformation.aspx?paperID=24490

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters